N5521
α(2→3,6) Neuraminidase from Clostridium perfringens (C. welchii)
recombinant, expressed in E. coli, buffered aqueous solution, ≥250 units/mg protein
Sinónimos:
Acyl-Neuraminyl Hydrolase, Sialidase
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Specific activity:
≥250 units/mg protein
Recombinant:
expressed in E. coli
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
recombinant
expressed in E. coli
form
buffered aqueous solution
specific activity
≥250 units/mg protein
mol wt
~41 kDa
foreign activity
proteases, none detected
shipped in
wet ice
storage temp.
2-8°C
Biochem/physiol Actions
Releases α(2→3)- and α(2→6)-linked N-acetylneuraminic acid from complex oligosaccharides.
Packaging
Provided with 5× reaction buffer (250 mM sodium phosphate, pH 6.0).
Physical form
Solution in 20 mM Tris-HCl, pH 7.5, and 25 mM NaCl.
Preparation Note
Expressed in glycosidase-free hosts.
Other Notes
One unit will hydrolyze 1 μmole of 4-methylumbelliferyl α-D-N-acetylneuraminide per min at pH 5.0 at 37 °C
signalword
Danger
hcodes
pcodes
Hazard Classifications
Resp. Sens. 1
Clase de almacenamiento
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Contenido relacionado
Datasheet
Rodolfo Ocadiz-Delgado et al.
BMC infectious diseases, 13, 20-20 (2013-01-19)
In April 2009, public health surveillance detected an increased number of influenza-like illnesses in Mexico City's hospitals. The etiological agent was subsequently determined to be a spread of a worldwide novel influenza A (H1N1) triple reassortant. The purpose of the
Weijia Wang et al.
Journal of virology, 87(8), 4642-4649 (2013-02-15)
In 2009, we successfully produced a high-yield live attenuated H1N1pdm A/California/7/2009 vaccine (CA/09 LAIV) by substitution of three residues (K119E, A186D, and D222G) in the hemagglutinin (HA) protein. Since then, we have generated and evaluated additional H1N1pdm vaccine candidates from
Charles R Beck et al.
Influenza and other respiratory viruses, 7 Suppl 1, 14-24 (2013-02-12)
The objectives of this study were to: (1) reflect on key stages in the discovery, development and pre-pandemic use of neuraminidase inhibitors (NAIs), (2) summarise the evidence of NAI effectiveness for treatment and prophylaxis of seasonal influenza prior to the